Megga Mix financial benefit

CDI Prevention Cost-Benefit Analysis

MEGGA MIX Cost-Benefit Analysis

Evaluating the financial impact for Clostridioides difficile infection in Florida hospitals

Susceptible Patients in Florida
680,000 per year
CDI Treatment Cost
$30,000 per case
Preventive Treatment Cost
$500 per patient
Preventive Efficacy
90%

Cost-Benefit Analysis

The following analysis evaluates the financial impact of implementing a preventive treatment program across different infection rates.

Prevention Cost = $500 (Program Cost = $340,000,000)

Infection Rate Expected CDI Cases Avoided Cases (90%) Avoided Treatment Cost Program Cost Net Savings ROI
1.0% 6,800 6,120.0 $183,600,000 $340,000,000 −$156,400,000 0.54
2.0% 13,600 12,240.0 $367,200,000 $340,000,000 $27,200,000 1.08
3.0% 20,400 18,360.0 $550,800,000 $340,000,000 $210,800,000 1.62
4.0% 27,200 24,480.0 $734,400,000 $340,000,000 $394,400,000 2.16
5.0% 34,000 30,600.0 $918,000,000 $340,000,000 $578,000,000 2.70
Scroll horizontally to view full table

Estimated Baseline CDI Rate in the Specified Florida Cohort

Based on a review of recent CDC data (2022–2023), peer-reviewed studies, and NHSN surveillance reports, the baseline hospital-onset CDI (HO-CDI) incidence in high-risk populations like elderly (≥65 years) hospitalized patients on antibiotics is estimated at 2.5–3.5% in US hospitals, with no significant deviations for Florida specifically.

Key Takeaways

  • With 90% effectiveness, the preventive becomes cost-saving at ≥ ~1.85% infection rate.
  • Infection rates of 3%–5% produce substantial net savings (hundreds of millions of dollars).
  • At a 3% infection rate, the program yields $210.8M in net savings.

This analysis demonstrates that implementing a preventive treatment program for CDI in Florida hospitals can yield significant financial benefits, particularly at infection rates of 2% or higher.

Visit www.MeggaMix.com

MEGGA MIX Cost-Benefit Analysis | Data based on Florida hospital statistics and treatment costs

© 2025 Healthcare Analytics. All rights reserved.